Compared to Estimates, Health Catalyst (HCAT) Q4 Earnings: A Look at Key Metrics

Core Insights - Health Catalyst reported revenue of $79.61 million for the quarter ended December 2024, reflecting a 6% increase year-over-year, but fell short of the Zacks Consensus Estimate of $79.83 million by 0.28% [1] - The company's EPS was $0.04, an increase from $0.02 in the same quarter last year, but significantly below the consensus estimate of $0.11, resulting in an EPS surprise of -63.64% [1] Revenue Breakdown - Professional services revenue was $28.01 million, slightly below the five-analyst average estimate of $29 million, with a year-over-year change of +0.1% [4] - Technology revenue reached $51.60 million, exceeding the five-analyst average estimate of $50.83 million, marking a year-over-year increase of +9.6% [4] Profitability Metrics - Adjusted Gross Profit for Professional Services was reported at $3.78 million, slightly below the average estimate of $3.81 million from five analysts [4] - Adjusted Gross Profit for Technology was $33.35 million, surpassing the average estimate of $32.89 million from five analysts [4] Stock Performance - Over the past month, shares of Health Catalyst have returned -14.7%, compared to a -2.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]